Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
about
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to dateReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabDOACs - advances and limitations in real worldNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewRecent advances in the development of specific antidotes for target-specific oral anticoagulantsA clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.Effect of Catnip Charcoal on the In Vivo Pharmacokinetics of the Main Alkaloids of Rhizoma Coptidis.Strategies for urgent reversal of target-specific oral anticoagulants.Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis.Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.How to effectively manage the event of bleeding complications when using anticoagulants.Who, when, and how to reverse non-vitamin K oral anticoagulants.Clinical implications of reversal agents for direct oral anticoagulants.Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.Drug Treatment of Venous Thromboembolism in the Elderly.Apixaban: A Review in Venous Thromboembolism.Managing the perioperative patient on direct oral anticoagulants.Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants.Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation.Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants.New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery.Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.Evaluation of Clopidogrel Conjugation Metabolism: PK Studies in Man and Mice of Clopidogrel Acyl Glucuronide.Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.Antidotes to non-vitamin K oral anticoagulants: necessary or not?Effect of Activated Charcoal on Rivaroxaban Complex Absorption.Anti-Xa activity in apixaban overdose: a case report.Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
P2860
Q26764874-9F7BD1A5-66CD-468D-A145-E6102235A369Q26764882-97E5D693-F664-4149-9C9D-0996D150E043Q28070132-FB976F12-3F49-4E3D-BF95-9427243D90C8Q28081918-4C6E584C-844B-4A85-9A8E-96C80408F614Q28256340-D407C01D-9679-43EB-BAEE-396073AD3462Q34109813-729DF8AB-202D-4EFC-8F2F-82E7F6043C32Q34469002-C9812466-E54F-462D-8DBF-BF7B69EC49D0Q34688742-50CD710F-CF52-47AA-B32B-25C15414A9A5Q35986742-943C1283-E178-4D6E-B8A6-5BE17DF5621EQ36321564-D60AAB4E-16ED-4497-8A9C-2DC52C73171FQ36980358-41E105D1-4664-4BAA-A85F-28614AE37510Q38285105-BA9E73CA-79C8-4614-912F-BCD51FC84B55Q38287151-5279F1BF-68E5-4964-AAE6-EF204B68C97FQ38448388-DCA89ED7-F5AC-4F9F-8BFC-98AA51172BE7Q38602484-CF9DD96B-83D0-47B8-B3DB-15817E20F95EQ38631033-1B1FD9BD-ED4B-4FC8-8474-A62DA2610291Q38634835-9219AA60-C986-4F2D-8E81-BDA9FD229A2BQ38655960-A64C40AF-ACBE-4A6B-903D-4EE6D85B34F1Q38757405-5C696086-989C-4490-9C02-9D620F379DD9Q38803293-2455E171-1DE7-4B3B-B14E-EF40A25E9321Q38838530-65202EDA-BE99-40BC-BD69-EB5E42E6064EQ38851927-62FDE8A9-ECFE-45AD-832E-387FDFBD5432Q38960858-1669DA8F-900F-43A3-A808-D78533DA480BQ39253985-C83FCF3D-8A8D-4863-98D2-2F867CA08CEAQ39456624-AA783B4F-EE7E-4219-AA05-96DB07CF61F6Q40081589-F10E1AA8-E29E-48E1-8450-45426A54C852Q42072098-6374CF70-C62B-46C9-B2C5-30A86E20B37BQ42256340-064FC398-D2C8-498B-940A-80E45DEF3496Q47099414-FB908C8B-E03F-4135-829A-4E420351F87AQ48248862-A22922FD-C78C-4F3C-A987-809D49BC5A4CQ48599279-CB9FBAA4-E64B-463E-9E7B-9711C8D42152Q48606651-8BCD8F64-BB34-48FF-B2C5-DC6229C3332AQ48948394-27E9998E-832F-4273-AF9A-45059C8A67A5Q50963192-67B0E5AD-CBBA-4012-9A61-710B922766D4Q51032306-A5655D97-66A6-4C54-867F-DEA047552B07Q51629843-1ADEC2B6-4E8E-4731-B02D-F96A9BCB31EDQ53218072-01F8F16F-2404-4125-9C9D-2BE286D45CE5
P2860
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@en
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@nl
type
label
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@en
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@nl
prefLabel
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@en
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@nl
P2093
P2860
P1476
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.
@en
P2093
Charles Frost
Donglu Zhang
Giridhar Tirucherai
Jessie Wang
Rebecca A Boyd
Sabiha Mondal
Xiaoli Wang
P2860
P2888
P304
P356
10.1007/S40256-013-0055-Y
P577
2014-04-01T00:00:00Z